Literature DB >> 25172415

A novel selective multikinase inhibitor of ROCK and MRCK effectively blocks cancer cell migration and invasion.

Vijay Pralhad Kale1, Jeremy A Hengst1, Dhimant H Desai1, Taryn E Dick1, Katherine N Choe1, Ashley L Colledge1, Yoshinori Takahashi1, Shen-Shu Sung1, Shantu G Amin1, Jong K Yun2.   

Abstract

Two structurally related protein kinase families, the Rho kinases (ROCK) and the myotonic dystrophy kinase-related Cdc42-binding kinases (MRCK) are required for migration and invasion of cancer cells. We hypothesized that simultaneous targeting of these two kinase families might represent a novel therapeutic strategy to block the migration and invasion of metastatic cancers. To this end, we developed DJ4 as a novel small molecule inhibitor of these kinases. DJ4 potently inhibited activities of ROCK and MRCK in an ATP competitive manner. In cellular functional assays, DJ4 treatment significantly blocked stress fiber formation and inhibited migration and invasion of multiple cancer cell lines in a concentration dependent manner. Our results strongly indicate that DJ4 may be further developed as a novel anti-metastatic chemotherapeutic agent for multiple cancers.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; MRCK; Migration; Multikinase inhibitor; ROCK; Stress fibers

Mesh:

Substances:

Year:  2014        PMID: 25172415      PMCID: PMC4182185          DOI: 10.1016/j.canlet.2014.08.032

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  43 in total

Review 1.  Rocks: multifunctional kinases in cell behaviour.

Authors:  Kirsi Riento; Anne J Ridley
Journal:  Nat Rev Mol Cell Biol       Date:  2003-06       Impact factor: 94.444

Review 2.  PAK and other Rho-associated kinases--effectors with surprisingly diverse mechanisms of regulation.

Authors:  Zhou-shen Zhao; Ed Manser
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

Review 3.  Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.

Authors:  Peichen Pan; Mingyun Shen; Huidong Yu; Youyong Li; Dan Li; Tingjun Hou
Journal:  Drug Discov Today       Date:  2013-09-25       Impact factor: 7.851

4.  The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton.

Authors:  T Leung; X Q Chen; E Manser; L Lim
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

5.  p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions.

Authors:  T Ishizaki; M Naito; K Fujisawa; M Maekawa; N Watanabe; Y Saito; S Narumiya
Journal:  FEBS Lett       Date:  1997-03-10       Impact factor: 4.124

6.  Rho GTPases are over-expressed in human tumors.

Authors:  G Fritz; I Just; B Kaina
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

7.  Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis.

Authors:  Erik Sahai; Christopher J Marshall
Journal:  Nat Cell Biol       Date:  2003-08       Impact factor: 28.824

8.  Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma.

Authors:  Masahide Nakajima; Kazutaka Hayashi; Yasuhiro Egi; Ken-ichi Katayama; Yusaku Amano; Masayoshi Uehata; Makio Ohtsuki; Akihiro Fujii; Koh-ichi Oshita; Hirotoshi Kataoka; Kenji Chiba; Nobuharu Goto; Takao Kondo
Journal:  Cancer Chemother Pharmacol       Date:  2003-05-29       Impact factor: 3.333

9.  Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer.

Authors:  Takao Kamai; Tomonori Yamanishi; Hiromichi Shirataki; Kentaro Takagi; Hidekazu Asami; Yuji Ito; Ken-Ichiro Yoshida
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

Review 10.  Myosin phosphatase: structure, regulation and function.

Authors:  Masaaki Ito; Takeshi Nakano; Ferenc Erdodi; David J Hartshorne
Journal:  Mol Cell Biochem       Date:  2004-04       Impact factor: 3.396

View more
  13 in total

Review 1.  The Rho GTPase signalling pathway in urothelial carcinoma.

Authors:  Solomon L Woldu; Ryan C Hutchinson; Laura-Maria Krabbe; Oner Sanli; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

2.  Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.

Authors:  Alison M Kurimchak; Carlos Herrera-Montávez; Jennifer Brown; Katherine J Johnson; Valerie Sodi; Nishi Srivastava; Vikas Kumar; Safoora Deihimi; Shane O'Brien; Suraj Peri; Gina M Mantia-Smaldone; Angela Jain; Ryan M Winters; Kathy Q Cai; Jonathan Chernoff; Denise C Connolly; James S Duncan
Journal:  Sci Signal       Date:  2020-02-18       Impact factor: 8.192

Review 3.  Targeting the cytoskeleton against metastatic dissemination.

Authors:  Carmen Ruggiero; Enzo Lalli
Journal:  Cancer Metastasis Rev       Date:  2021-01-20       Impact factor: 9.264

Review 4.  Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.

Authors:  Zhongwei Liu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2018-02-13       Impact factor: 5.858

Review 5.  Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma.

Authors:  Margaret L Gulley
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

6.  Pragmatic medicine in solid cancer: a translational alternative to precision medicine.

Authors:  Jan Brábek; Daniel Rosel; Michael Fernandes
Journal:  Onco Targets Ther       Date:  2016-04-05       Impact factor: 4.147

Review 7.  Novel Insights into the Roles of Rho Kinase in Cancer.

Authors:  Lei Wei; Michelle Surma; Stephanie Shi; Nathan Lambert-Cheatham; Jianjian Shi
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-01-02       Impact factor: 4.291

8.  Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer.

Authors:  Mathieu Unbekandt; Simone Belshaw; Justin Bower; Maeve Clarke; Jacqueline Cordes; Diane Crighton; Daniel R Croft; Martin J Drysdale; Mathew J Garnett; Kathryn Gill; Christopher Gray; David A Greenhalgh; James A M Hall; Jennifer Konczal; Sergio Lilla; Duncan McArthur; Patricia McConnell; Laura McDonald; Lynn McGarry; Heather McKinnon; Carol McMenemy; Mokdad Mezna; Nicolas A Morrice; June Munro; Gregory Naylor; Nicola Rath; Alexander W Schüttelkopf; Mairi Sime; Michael F Olson
Journal:  Cancer Res       Date:  2018-01-30       Impact factor: 12.701

9.  New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment.

Authors:  Giovanni Cugliari; Alessandra Allione; Alessia Russo; Chiara Catalano; Elisabetta Casalone; Simonetta Guarrera; Federica Grosso; Daniela Ferrante; Marika Sculco; Marta La Vecchia; Chiara Pirazzini; Roberta Libener; Dario Mirabelli; Corrado Magnani; Irma Dianzani; Giuseppe Matullo
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 10.  Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges.

Authors:  Aneta Gandalovičová; Daniel Rosel; Michael Fernandes; Pavel Veselý; Petr Heneberg; Vladimír Čermák; Luboš Petruželka; Sunil Kumar; Victoria Sanz-Moreno; Jan Brábek
Journal:  Trends Cancer       Date:  2017-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.